Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. John Marshall, Chief, Division of Hematology/Oncology at Georgetown University, and Dr. Tony Shields, Associate Center Director, Clinical Sciences at Karmanos Cancer Center Institute. Both are co-authors on the December 8, 2020 paper: Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer found in Clinical Cancer Research, a journal of the American Association for Cancer Research.

In this interview Dr. Marshall and Dr. Shields discuss the findings of their paper and how we can better predict which metastatic colorectal cancer patients will benefit from first-line FOLFOX+BV followed by FOLFIRI+BV or vice versa.

For more information, please visit: www.CarisLifeSciences.com/MI-FOLFOXai/

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Marcus Neubauer, Chief Medical Officer of the US Oncology Network, to discuss the challenges and opportunities of precision oncology in the community setting and how it is evolving.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Tian Zhang, Assistant Professor of Medicine at Duke University, to discuss the recent advances in prostate cancer and abstracts that were presented at this year's virtual ASCO meeting.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Virginia Kaklamani from the University of Texas Health San Antonio, to discuss changes in the approach to both metastatic breast cancer and early stage breast cancer, and how these changes are impacting patient care.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman Dr. Chadi Nabhan sits down with patient advocate Laura Holmes Haddad to discuss her personal journey with breast cancer and precision oncology.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Geoff Gibney from Georgetown University to discuss evolving strategies in treating melanoma in the era of precision oncology.

For more information, please visit: www.CarisLifeSciences.com

oncologyprecisionmedicine

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Michael Korn, Chief Medical Officer at Caris Life Sciences®, to discuss the MI FOLFOXai™ predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer.

For more information, please visit: www.CarisLifeSciences.com/MI-FOLFOXai/

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Tian Zhang, Assistant Professor of Medicine at Duke University to discuss the recent advances and data in urothelial cancer presented at this year's virtual ASCO meeting.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Stephen Liu from MedStar Georgetown University Hospital to discuss the latest lung cancer updates presented at this year's ASCO meeting.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. David Spetzler, President and Chief Scientific Officer at Caris Life Sciences®, to discuss precision medicine.

For more information, please visit: www.CarisLifeSciences.com